【PharmaEssentia】February 2026 Revenue Reaches 1.60 Billion (YoY +56.7%)
PharmaEssentia, a new drug development company, announced that its revenue for February 2026 reached 1.60 billion, a year-over-year increase of 56.7%. This strong performance is primarily attributed to the sales of its new drug for treating polycythemia vera, highlighting its success in the biotechnology and healthcare market.
📋 Article Processing Timeline
- 📰 Published: February 1, 2026 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (1559h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:19 (16h 19m after Collected)
Stock Code: 6446
Company Name: PharmaEssentia Corp.
Industry: Biotechnology & Medical Care
Data for: 2026-02
Monthly Revenue: 1,600,454 (in thousands of NTD), or 1.60 billion
Year-over-Year Change: +56.7%
Company Name: PharmaEssentia Corp.
Industry: Biotechnology & Medical Care
Data for: 2026-02
Monthly Revenue: 1,600,454 (in thousands of NTD), or 1.60 billion
Year-over-Year Change: +56.7%